Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioWorld's headline "Zealand, Wyeth Collaborate On Gap Junction Modulators" (Cormac Sheridan) documents the original 2003 discovery alliance that the parties…
Authors describe "(2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134), an orally active small molecule gap-junction…
Rotigaptide "acts at connexins, preferentially to connexin 43 (Cx43)" and is "a drug under clinical investigation for the treatment of cardiac arrhythmias –…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Wyeth and Zealand expand 3-year discovery collaboration in gap junction modulators (cardiovascular and beyond).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Wyeth Pharmaceuticals / Zealand Pharma A/S (this deal) | 2005 | — | — |
| Wyeth Pharmaceuticals / Progenics Pharmaceuticals, Inc. | 2005 | $416M | — |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2005 deals